Funded project
IP-NFT
Discovering Novel Autophagy Activators - Korolchuk Lab

Discovering Novel Autophagy Activators - Korolchuk Lab

Autophagy
Neurodegeneration
Ageing
Autophagy - the mechanism to recycle cellular components - becomes dysregulated with age and is associated with numerous diseases. The Korolchuk lab, based at Newcastle University, will screen a compound library to identify novel autophagy-activating compounds with the aim of restoring autophagy function to aged cells.
Funding
$ 285,000
Initiated
14.12.2021
Approval
100% Voted Yes
Korolchuk Bio
Viktor Korolchuk
Research Lead and Cell Biology
Jóhannes Reynisson
Drug Discovery
Konstantin Volcho
Organic and Medicinal Chemistry
AT A GLANCE

Stage
Early stage preclinical discovery

Area
Drug discovery

Status
Ongoing

Patent Status
Not filed yet

PROJECT LINKS

Background

Ageing is associated with the decline in the capacity of the autophagy pathway to degrade dysfunctional and damaging cellular components, such as protein aggregates and mitochondria. Dysfunctional autophagy, in turn, undermines other cellular functions including DNA repair, metabolism and survival. Therefore, activation of autophagy is considered a promising therapeutic approach to combat ageing and age-related diseases.

Aims, Hypothesis & Results

Lysosomal dysfunction is an important factor contributing to the reduction of autophagy during aging. As dysfunctional lysosomes interfere with autophagy at the terminal stage, stimulation of autophagy initiation can be ineffective to rescue autophagy. Additionally, current methods to measure autophagy are rather unreliable, slow, and with complicated readouts, making the screening of compounds that promote autophagy less efficient. To model lysosomal dysfunction, Prof. Korolchuk lab uses cells with a mutation in a lysosomal protein (Npc1) associated with neurodegenerative diseases. When these cells are subjected to metabolic stress, they suffer cell death due to dysfunctional autophagy, providing an easy readout for an autophagy assay (cells dead/cells alive). To identify true autophagy activators, Prof. Korolchuk lab uses cells that lack initiation of autophagy and are therefore not rescuable by autophagy inducers in parallel with Npc1 KO cells.

Korolchuck lab proposes to initiate a drug discovery program with the aim of identifying novel bioactive autophagy inducers.

Timeline

The Korolchuk Lab is currently in the midst of Pre-Clinical Studies 1, which focuses on identifying lead compounds from a diverse library of naturally occurring bioactive compounds. Upon the identification of promising lead compounds, Pre-Clinical Studies 2 will commence, involving the synthesis and testing of these compounds. If successful, Pre-Clinical Studies 3 will follow, encompassing the evaluation of the lead compounds in mouse models to assess their absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties.

Pre-Clinical Studies 1: Identification of Lead Compounds
Required Funding: $85,000
Duration: 12 Months

Pre-Clinical Studies 2: Synthesis and Testing
Required Funding: $20,000
Duration: 2 Months

Pre-Clinical Studies 3: Future Work Upon Lead Identification
Required Funding: $30,000
Duration: 6 Months

VitaDAO Board Evaluation Writeup

All the VitaDAO evaluators considered this project worthy of funding. The assay has an easy readout, decent throughput, good controls and targeting one of the most important processes in cellular aging (autophagy). Proof-of-principle was already in place, as Korolchuk Lab had previously identified hits with this approach by screening an FDA-approved compound library. The screening platform would also allow collaboration with other projects targeting autophagy/mitophagy and has potential for generation of IP/NFT for compounds. Risks to consider are the necessity for the screen to provide hits and that the specific knockout model they are using translates to having general relevance in ageing. However, the team is working on addressing the latter risk, with promising data suggesting this might not be a problem.

Projects supported
No items found.

Latest Project Updates

No items found.
14
December
2021
Project Initiated!

Discover more projects & initiatives

The Longevity Prize

Initiative

The Longevity Prize is a series of prizes to award and accelerate progress in longevity and rejuvenation research. It was initiated by VitaDAO and funded through donations through our gitcoin quadratic donation round and partnered with Foresight Institute, Methuselah Foundation and Lifespan.

$ 24,000
allocated
View Project

The VitaDAO Longevity Fellowship

Initiative

The VitaDAO Longevity Fellowship is aimed at distributing need-based micro grants to help students and early career stage individuals with interest in longevity get more deeply involved in longevity. This is aimed at activities ranging from short term research to attending a conference, or joining a program such as the Longevity Biotech Fellowship.

$ 20,000
allocated
View Project

Humanity - Proprietary Aging Score App

Equity

Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.

$ 50,000
allocated
View Project

Matrix Bio - Long-lived Species Inspired Longevity Biotech

IP-NFT

VitaDAO and the Gorbunova Lab are launching Matrix Bio, a cutting-edge research venture leveraging the anti-cancer and pro-longevity effects of high molecular weight hyaluronic acid from naked mole rats to humans.

$ 300,000
allocated
View Project

Are you working on the next longevity science breakthrough?

Click here to explore the VitaDAO Project Funding FAQ.